Call for Papers  

Article Details


Systematic Review Article

A Systematic Patent Review (2008-2023) for Treatment in Pregnancy

Author(s):

Kélle Velasques Pereira, Camila Oliveira Pacheco, Izabel Almeida Alves and Sandra Elisa Haas*   Pages 1 - 18 ( 18 )

Abstract:


Introduction: During pregnancy, the woman’s body undergoes anatomical and physiological changes, making this period susceptible to maternal-fetal diseases and complications. The consequences of not treating pregnant women include premature birth, low birth weight fetuses, and postnatal behavior disorders. Developing new therapies can accelerate the discovery of safe and effective drugs, contributing to designing novel natural and synthetic products to treat complications the pregnancy.

Objective: This study aimed to carry out a patent review to identify and explore trends in innovation and therapeutic strategies for treating pregnant women.

Methods: The Espacenet and WIPO databases were used, with the inclusion criteria being the keywords “pregnancy and drug” and code A61k, from 2008 to 2023, and as exclusion were the access to the patent and focus on human pregnant women.

Results: After the final screening, 32 patents were selected, with strategies for the treatment of diseases in pregnant women. Of these, 20 patents are on preclinical studies on animals and 12 on pregnant women. It was observed that universities lead the ranking of applications (17/32), and China has the highest number of patents (18/32). Most findings contain herbal medicines and/or the association of natural extracts with synthetic drugs.

Conclusion: From this perspective, new drug administration systems were also developed, which can be a promising source for obtaining new medicines for the treatment of pregnant women; however, research is still limited and shows a gap in stimulating the rapid development of safe drugs that improve the health of pregnant women.

Keywords:

pregnancy,drug,diseases,natural products,medicinal,innovation

Affiliation:



Read Full-Text article